SeaDragon is fortunate to have the support of several high-calibre investors.
PESCADO HOLDINGS LIMITED is an investment company of the Christchurch-based Stewart family. The Stewart family have been a long term investor in a number of companies and have been active in sectors as diverse as plastics, healthcare, and pet nutrition. Masthead Limited, via its subsidiary Pescado Holdings, became a shareholder in 2016 and currently holds a 47.7% stake in SeaDragon.
SEASPREN LIMITED is an investment company of the American-based Stormlight Holdings. They are a long term investor in a number of companies, and prioritize partnering with business operators who are aligned with their investment philosophy of curiosity and flexible thinking. Stormlight Holdings, via its subsidiary Seaspren Limited became a shareholder in 2020 and currently holds a 11.4% Stake in SeaDragon
BIOSCIENCE MANAGERS is a leading specialist healthcare fund manager, headquartered in Melbourne, Australia. It was established in 2003 as a direct descendant of the Rothschild Bioscience Unit (1987-2000) which was the largest non US specialty biotechnology fund manager globally. The BioScience Managers team brings to SeaDragon experience in more than 170 investments in the healthcare and life science sectors. It has been a SeaDragon investor since 2012 and currently holds a 7.8% stake in the Company.
SDMO TRUSTEE is the private investment vehicle of SeaDragon Director Stuart Macintosh. Stuart is one of SeaDragon’s largest and longest-standing shareholders. He began backing the Company before it was listed on the NZX in 2012. SDMO Trustee currently holds a 2.9% stake in SeaDragon.
Please Note: These proportional holdings in SeaDragon are subject to change; The company has also in place Pescado a further $4.0m convertible loan note facility that will mandatory convert to shares at $0.20 per share at 31 March 2021.